Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Less than a month after rebranding from JDRF to Breakthrough T1D, the leading type 1 diabetes advocacy organization has now released new consensus guidance related to the monitoring of early-stage type 1 diabetes. Debuted on the final day of the 84th American Diabetes Association Scientific Sessions , the consensus document seeks to fill a gap in guidance around autoantibody-positive individuals i...

At the 84th American Diabetes Association (ADA) Scientific Sessions , INHALE-3 was among the trials to take center stage. A phase 4 trial comparing the use of inhaled insulin (Afrezza) against standard care, results demonstrated use of inhaled insulin, in addition to insulin degludec, was associated with improved HbA1c in patients with type 1 diabetes , with an improvement of 0.5% or greater obser...

Despite being a chronic autoimmune disease, the burden of type 1 diabetes is often overlooked in public health discussions. Not only are patients with type 1 diabetes being tasked with understanding disease pathophysiology as an integral part of optimal management, but also with keeping up with advances in pharmacotherapy and technology. As a result, patient support programs, such as Blue Circle H...

In this special edition episode from the 84th American Diabetes Association Scientific Sessions , hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Davida Kruger, NP, a certified nurse practitioner in the Division of Endocrinology at Henry Ford Health System in Detroit. During the episode, Kruger takes hosts on a deep dive into the latest in diabetes technology at the meeting, wi...

On the opening day of the 84th American Diabetes Association Scientific Sessions , the ADA ushered in a new era for their organization with the announcement of the formation of the Obesity Association. Created more than a decade after the American Medical Association recognized obesity as a disease, the new subdivision of the ADA was created to further the organization’s mission of advocating for...

In this special edition recorded at the 84th American Diabetes Association Scientific Sessions , Carol Levy, MD, director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research, joins the podcast for a deep dive into the INHALE-3 trial and how to incorporate individual patient-level factors into the management strategy of patients with type 1 diabetes who could benefit from inhal...

This special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives focuses on top highlights and updates in diabetes technology from the 84th American Diabetes Association Scientific Sessions . In the episode, hosts Omnipod 5 and the SECURE-T2D trial, a study comparing use of simplified meal announcement vs precise carbohydrate counting with the Medtronic Mi...

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management. In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott...

In this episode, hosts provide their audience with an overview of a pair of new studies on the topic of diabetes in pregnancy: the GLAM and CRISTAL studies.

To celebrate the FLOW trial and break down what it means for people with type 2 diabetes and CKD, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recorded a special edition episode to discuss the clinical application of this trial, unmet need in CKD management, the future of incretin therapies, and more! Chapters: 00:00 - Intro  00:40 - FLOW Background 02:55 - FLOW Results 07:08 - Combinatio...

The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024 , the pair of recommendations reflect the findings from a systematic review and network meta-analy...

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.

The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes , the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and...

In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 receptor agonist use and CGM technology, updates in on...

In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health. During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advancement in pharmaco...

Hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives recorded a special edition episode with Jake Leach, chief operating officer of Dexcom. The episode itself represents a follow-up to a conversation a year ago at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2023, where Leach discussed the ongoing global rollout of the Dexcom...

W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more...

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies. Chapters: 00:35 - Guest Introduction 01:10 - SELECT Results Overview 04:25 - Next Steps for Research 07:15 - Mechani...

In this episode, the hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors. Video version: https://www.hcplive.com/view/diabetes-dialogue-understanding-mard-comparing-popular-cgm-sensors Key Highlights: 00:35 - The Myth of MARD 04:10 - Considerations When Interpret...

In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting’s annual yearbook session encapsulates the exciting developments within the field. Video Version: https://www.hcplive.com/view/diabetes-dialogue-attd-2024-preview   Key Highlights:  01:05 - Bellini’s ATTD Pi...

The introduction of CGM in 1999 completely shifted the trajectory of care for people with diabetes. Now, new data suggest advanced CGM metrics, such as time in range, are proving comparable to HbA1c for predicting diabetic retinopathy and other microvascular outcomes. In this episode, Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range and...

In this episode, hosts are joined by Shah for a discussion on his recent proof-of-concept study looking at tirzepatide in type 1 diabetes, the prospect of GLP-1 RA-based therapies in type 1 diabetes, and the potential roles for tirzepatide beyond T2D and weight management. Episode Highlights 00:00 - Intro 01:56 - Use of GLP-1s in T1D 05:32 - Study on Tirzepatide in T1D  10:04 - Insulin Use in Stud...

In this episode, hosts discuss recent news and updates in diabetes technology from Abbott, Dexcom, and Medtronic in the first half of January 2024. Episode Highlights 00:40 Abbott FreeStyle Libre 2 Plus 18:08 Dexcom Stelo 26:30 Medtronic Simplera Sync

In this episode, hosts sit down with Ralph DeFronzo, MD, for a discussion on how advances in management have transformed the diagnosis and management of hypercortisolism among people with type 2 diabetes. Episode Highlights 00:39 DeFronzo Introduction 01:54 Presentation of Hypercortisolism 05:50 Ominous Octet and Hypercortisolism 09:47 Prevalence of Hypercortisolism in T2D 13:57 Impact of Untreate...